Skip to main content

Table 3 HIV treatment and markers of immunity

From: HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya

Variable N Median (IQR) or n (%)
Duration since diagnosis of HIV (Months) 360 107.0 (71.5, 132.0)
 Range (Min. – Max.)   1.0–181.0
Duration before ART initiation (Months) 360 44.0 (4.5, 78.5)
 Range (Min. – Max.)   0.0–166.0
Duration of ART use (Months) 360 88.0 (51.0, 122.5)
 Range (Min. – Max.)   1.0–141.0
Duration of current ART (Months) 360 51.0 (17.0, 76.0)
 Range (Min. – Max.)   0.0–147.0
ART Line
 First line (NRTI + NNRTI) 360 286 (79.4%)
 Second line (NRTI + PI)   74 (20.6%)
Others
 Dapsone   5 (1.4%)
 Septrin 359 353 (98.3%)
 Septrin/Isoniazid   1 (0.3%)
Suppressed viral load (< 1000 copies/ml) 358 303 (84.6%)
Baseline CD4 cell count per mm3 304 243.0 (10.8.0, 399.0)
 Range (Min. – Max.)   1.0–1459.0
 < 200.0   122 (40.1%)
 200.0–499.0 304 132 (43.4%)
 ≥ 500.0   50 (16.4%)
Current CD4 cell count per mm3 360 491.0 (336.5, 701.0)
 Range (Min. – Max.)   1.0–1845.0
 < 200.0   33 (9.2%)
 200.0–499.0 360 153 (42.5%)
 ≥ 500.0   174 (48.3%)
WHO Clinical stage
 Stage 1   122 (35.6%)
 Stage 2 343 61 (17.8%)
 Stage 3   132 (38.5%)
 Stage 4   28 (8.2%)
  1. IQR Inter Quartile Range
  2. N is less than 360 in other variables due to missing data